Gain-of-function of IDH mutations occurs most frequently in low-grade glioma, cartilaginous tumors, intrahepatic cholangiocarcinoma, and certain hematological malignancies; and thus, the accumulation of D-2-HG occurs in these tumors [6]. Here, IDH1 is linked to chondrogenic neoplasm.